The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder impacting motor neurons, typically leading to fatality within 2-3 years of symptom onset.
• MicroRNAs (miRNAs) are small non-coding RNAs crucial for regulating gene expression post-transcriptionally.
• Identifying reliable biomarkers for ALS is critical for early diagnosis and therapeutic development.

Purpose of the Study:

• To systematically review and analyze existing studies on microRNA (miRNA) deregulation in Amyotrophic Lateral Sclerosis (ALS) patients.
• To identify consistent miRNA candidates that could serve as potential biomarkers for ALS diagnosis.
• To explore the potential of miRNA expression profiles for ALS specificity.

Main Methods:

• A comprehensive literature search was conducted on PubMed to identify studies investigating miRNAs in ALS patients.
• Data from human studies were analyzed and grouped to identify consistently deregulated miRNAs.
• Focus was placed on identifying miRNAs with robust evidence of altered expression in ALS.

Main Results:

• Studies on miRNAs in ALS patients have yielded heterogeneous results due to variations in tissues and subject populations.
• Consistent deregulation was observed for specific miRNAs, including miR-206, miR-133, miR-149, and miR-338-3p.
• Evidence suggests that specific combinations of deregulated miRNAs may form an ALS-specific expression profile.

Conclusions:

• Certain miRNAs, notably miR-206, miR-133, miR-149, and miR-338-3p, are consistently found to be deregulated in Amyotrophic Lateral Sclerosis (ALS).
• A unique miRNA expression signature may be associated with ALS, highlighting their potential as biomarkers.
• Further research is necessary to establish a scientific consensus on the utility of miRNAs as ALS biomarkers.